HMGB1-Driven Inflammation and Intimal Hyperplasia After Arterial Injury Involves Cell-Specific Actions Mediated by TLR4

Jingjing Cai; Hong Yuan; Qingde Wang; Huan Yang; Yousef Al-Abed; Zhong Hua; Jiemei Wang; Dandan Chen; Jinze Wu; Ben Lu; John P Pribis; Weihong Jiang; Kan Yang; David J Hackam; Kevin J Tracey; Timothy R Billiar; Alex F Chen

doi:10.1161/ATVBAHA.115.305789

HMGB1-Driven Inflammation and Intimal Hyperplasia After Arterial Injury Involves Cell-Specific Actions Mediated by TLR4

Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2579-93. doi: 10.1161/ATVBAHA.115.305789. Epub 2015 Oct 29.

Authors

Jingjing Cai¹, Hong Yuan¹, Qingde Wang¹, Huan Yang¹, Yousef Al-Abed¹, Zhong Hua¹, Jiemei Wang¹, Dandan Chen¹, Jinze Wu¹, Ben Lu¹, John P Pribis¹, Weihong Jiang¹, Kan Yang¹, David J Hackam¹, Kevin J Tracey¹, Timothy R Billiar¹, Alex F Chen²

Affiliations

¹ From the Center of Clinical Pharmacology of the Third Xiangya Hospital (J.C., H.Y., Q.W., Z.H., J. Wu), the Center of Vascular Disease and Translational Medicine (A.F.C.), Department of Cardiology of the Third Xiangya Hospital (J.C., H.Y., W.J., K.Y.), and Department of Hematology of the Third Xiangya Hospital (B.L.), Central South University, Changsha, China; Department of Surgery, University of Pittsburgh School of Medicine, PA (J.C., Q.W., Z.H., J. Wang, D.C., J. Wu, J.P.P., D.J.H., T.R.B., A.F.C.); and Laboratory of Biomedical Science, the Feinstein Institute for Medical Research, Manhasset, New York (H.Y., Y.A.-A., K.J.T.).
² From the Center of Clinical Pharmacology of the Third Xiangya Hospital (J.C., H.Y., Q.W., Z.H., J. Wu), the Center of Vascular Disease and Translational Medicine (A.F.C.), Department of Cardiology of the Third Xiangya Hospital (J.C., H.Y., W.J., K.Y.), and Department of Hematology of the Third Xiangya Hospital (B.L.), Central South University, Changsha, China; Department of Surgery, University of Pittsburgh School of Medicine, PA (J.C., Q.W., Z.H., J. Wang, D.C., J. Wu, J.P.P., D.J.H., T.R.B., A.F.C.); and Laboratory of Biomedical Science, the Feinstein Institute for Medical Research, Manhasset, New York (H.Y., Y.A.-A., K.J.T.). afychen@yahoo.com billiartr@upmc.edu.

Abstract

Objective: Endoluminal vascular interventions such as angioplasty initiate a sterile inflammatory response resulting from local tissue damage. This response drives the development of intimal hyperplasia (IH) that, in turn, can lead to arterial occlusion. We hypothesized that the ubiquitous nuclear protein and damage-associated molecular pattern molecule, high-mobility group box 1 (HMGB1), is one of the endogenous mediators that activates processes leading to IH after endoluminal injury to the arterial wall. The aim of this study is to investigate whether approaches that reduce the levels of HMGB1 or inhibit its activity suppresses IH after arterial injury.

Approach and results: Here, we show that HMGB1 regulates IH in a mouse carotid wire injury model. Induced genetic deletion or neutralization of HMGB1 prevents IH, monocyte recruitment, and smooth muscle cell growth factor production after endoluminal carotid artery injury. A specific inhibitor of HMGB1 myeloid differentiation factor 2-toll-like receptor 4 (TLR4) interaction, P5779, also significantly inhibits IH. HMGB1 deletion is mimicked in this model by global deletion of TLR4 and partially replicated by myeloid-specific deletion of TLR4 but not TLR2 or receptor for advanced glycation endproducts deletion. The specific HMGB1 isoform known to activate TLR4 signaling (disulfide HMGB1) stimulates smooth muscle cell to migrate and produce monocyte chemotactic protein 1/CCL2) via TLR4. Macrophages produce smooth muscle cell mitogens in response to disulfide HMGB1 also in a TLR4/myeloid differentiation primary response gene (88)/Trif-dependent manner.

Conclusions: These findings place HMGB1 and its receptor, TLR4 as critical regulators of the events that drive the inflammation leading to IH after endoluminal arterial injury and identify this pathway as a possible therapeutic target to limit IH to attenuate damage-associated molecular pattern molecule-mediated vascular inflammatory responses.

Keywords: HMGBI protein; angioplasty; carotid artery injuries; hyperplasia; macrophages.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adaptor Proteins, Vesicular Transport / metabolism
Animals
Carotid Arteries / metabolism*
Carotid Arteries / pathology
Carotid Artery Injuries / genetics
Carotid Artery Injuries / metabolism*
Carotid Artery Injuries / pathology
Cell Movement
Cell Proliferation
Cells, Cultured
Chemotaxis, Leukocyte
Cytokines / metabolism
Disease Models, Animal
HMGB1 Protein / deficiency
HMGB1 Protein / genetics
HMGB1 Protein / metabolism*
Humans
Hyperplasia
Inflammation Mediators / metabolism
Macrophages, Peritoneal / metabolism
Mice, Inbred C57BL
Mice, Knockout
Myeloid Differentiation Factor 88 / genetics
Myeloid Differentiation Factor 88 / metabolism
Myocytes, Smooth Muscle / metabolism
Myocytes, Smooth Muscle / pathology
Neointima*
Signal Transduction
Time Factors
Toll-Like Receptor 4 / deficiency
Toll-Like Receptor 4 / genetics
Toll-Like Receptor 4 / metabolism*
Vascular System Injuries / genetics
Vascular System Injuries / metabolism*
Vascular System Injuries / pathology
Vasculitis / genetics
Vasculitis / metabolism*
Vasculitis / pathology

Substances

Adaptor Proteins, Vesicular Transport
Cytokines
HMGB1 Protein
HMGB1 protein, human
HMGB1 protein, mouse
Inflammation Mediators
Myd88 protein, mouse
Myeloid Differentiation Factor 88
TICAM-1 protein, mouse
TLR4 protein, human
Tlr4 protein, mouse
Toll-Like Receptor 4

Abstract

Publication types

MeSH terms

Substances

Grants and funding